Primary Outcome Measures the comparison of prevalence of germline mutations in MPM patients vs asbestos exposed healthy subjects Secondary Outcome Measures Secondary aim will be the comparison of overall survival (OS) according to mutational status in MPM patients. Inclusion Criteria Inclusion Criteria Cohort A: Patient with a documented diagnosis of[…]
Pleural Mesothelioma
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response rate of TNhYP218 CAR T cells in a limited number of participants with mesothelioma treated at the recommended phase 2[…]
Surgeries for Mesothelioma
Pleural mesothelioma is a very rare and aggressive cancer mainly caused by asbestos exposure. The survival time is very low, with people typically surviving around 9 to 20 months after treatment starts. The overall survival rate is around five percent, which means only five percent of people still live after[…]
Blood Biomarkers for Mesothelioma
A mesothelioma diagnosis is hard to receive and can be very overwhelming. Different research outcomes can help doctors and patients make better decisions though. One area of research is blood-based biomarkers. Two biomarkers that can help monitor mesothelioma include mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor[…]
Improving Mesothelioma Diagnosis
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos, mainly affects the pleura, the lining of the lungs. It also affects the peritoneum, which is the lining of the abdomen. It is very tough to diagnose mesothelioma, which leads to underdiagnosis of the disease. A study in Brazil’s Sao Paulo[…]
Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS)
Primary Outcome Measures The analysis of the primary efficacy endpoint will be conducted in all eligible patients, based on the disease control rate (DCR) at 12 weeks according to mRECIST 1.1 for mesothelioma, which was defined as the proportion of patients with compete response (CR), partial response (PR) or stable[…]
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures The diagnostic performance (sensitivity, specificity, positive predicative value, negative predicative value, and overall diagnostic accuracy – all parameters in %). in of FAPI PET compared to routine imaging modalities, including FDG PET/CT, in suspected PM lesions. Secondary Outcome Measures Calculate the proportion of patients where the location[…]
MARS 2 Trial for Mesothelioma
Malignant pleural mesothelioma is a deadly cancer mainly caused by asbestos exposure. It is a hard-to-treat cancer due to its aggressiveness. The cancer affects the pleura, which is the membrane that covers the lungs. A trial known as MARS 2 tried to find out if extended pleurectomy and decortication could[…]
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary[…]
Immune Checkpoint Inhibitors for the Treatment of Mesothelioma
Mesothelioma is a rare, aggressive cancer mainly caused by asbestos exposure. One treatment that is giving hope to patients and caregivers is the use of immune checkpoint inhibitors. A new study from Australia has raised questions about the effectiveness and safety of this novel treatment. In order to best care[…]
Skip to content